AI Stock Memo: COLL - Collegium Pharmaceutical - RankAlpha

COLL

AI Memo

Collegium Pharmaceutical

As of 2026-07-03/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q1 results showed JORNAY acceleration and pain-portfolio durability • 2026-05-07

Expected move: +29%

Biggest risk

The main bear read is that the thesis now relies heavily on acquisition integration, synergy capture, and sustained ADHD execution while also protecting pain-franchise durability; management also disclosed leadership departures around the time of the close, which adds execution noise. [#IR-2026-05-12]

Invalidation

Break below $29 or thesis failure.

What would change my mind?

The strongest supported bull read is that Collegium entered Q2 with a still-growing base business, then added AZSTARYS with an immediate guidance raise, giving the company a broader ADHD platform and a longer revenue runway. [#SEC-8K-2026-05-07][#IR-2026-05-12]

Research note

Recommendation

—

Confidence

medium

As of

2026-07-03

Base target

$45

p=45%

Bull target

$52

p=30%

Bear target

$29

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ADHD portfolio integration is now the main forward execution test
The strongest supported bull read is that Collegium entered Q2 with a still-growing base business, then added AZSTARYS with an immediate guidance raise, giving the company a broader ADHD platform and a longer revenue runway.
[#SEC-8K-2026-05-07][#IR-2026-05-12]

BearKey bullets

AZSTARYS integration may fail to deliver the expected revenue ramp, immediate accretion, or >$50M run-rate synergies within management’s timeline.
External coverage is thin, limiting confidence in post-deal estimate revisions and consensus validation.
Leadership changes disclosed alongside the acquisition close add transition risk during an integration period.

WatchKey bullets

Q1 results showed JORNAY acceleration and pain-portfolio durability

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $45 (p=45%)

Bull/Bear spread: +49% / -17%

Vs latest close: Bull +49% · Base +29% · Bear -17%

Scenario probabilities

Bull Target: $52 (p=30%)Base Target: $45 (p=45%)Bear Target: $29 (p=25%)

Commentary

Primary-source tone is constructive: Q1 execution was solid and the May 12 close brought a real guidance step-up. But coverage remains thin, the peer set is loose, and the thesis is now more integration-driven than sentiment-driven, so this still looks like a cautious monitoring-style positive rather than a clean high-conviction rerate. [#SEC-8K-2026-05-07][#IR-2026-05-12]

As of 2026-07-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ADHD portfolio integration is now the main forward execution test

Scenarios

Bull Target (Scenario probability)

$52 / p=30% prob

Base Target (Scenario probability)

$45 / p=45% prob

Bear Target (Scenario probability)

$29 / p=25% prob

Price $35 as of 2026-07-13

Nearest Scenario: Bear (∆ 17%)

Targets vs latest close: Bull +49% · Base +29% · Bear -17%

Sentiment & Exposure

News Sentiment (30d)

0.63

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Q1 results showed JORNAY acceleration and pain-portfolio durability
Collegium reported Q1 2026 net revenue of $193.5M, with JORNAY PM revenue up 36% year over year to $38.9M, pain portfolio net revenue up 4% to $154.6M, cash/marketable securities of $421.8M, and reaffirmed full-year 2026 guidance for the pre-AZSTARYS business. This supports the view that the base business was still executing before the portfolio step-up. [#SEC-8K-2026-05-07]
Prob 82.00% • Move 6.00% • Priced-in 70.00%
EVENT2026-05-12
AZSTARYS close raised 2026 revenue and EBITDA guidance
On May 12, 2026, Collegium completed the AZSTARYS acquisition and raised 2026 guidance to $865M-$895M of total product revenue and $475M-$500M of adjusted EBITDA, while stating the deal should be immediately accretive and extend revenue visibility through 2037. This is the clearest near-term rerating input in the packet. [#IR-2026-05-12]
Prob 78.00% • Move 8.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ADHD portfolio integration is now the main forward execution test
2027-05-12
The longer-duration case depends on integrating AZSTARYS into Collegium’s existing ADHD infrastructure, converting the added asset into the guided $60M-$70M of remainder-of-2026 revenue, and realizing more than $50M of annual run-rate synergies within twelve months without disrupting the legacy pain franchise. [#IR-2026-05-12]
Prob 60% • Move 12% • Priced-in 40%

Risks

AZSTARYS integration may fail to deliver the expected revenue ramp, immediate accretion, or >$50M run-rate synergies within management’s timeline.
External coverage is thin, limiting confidence in post-deal estimate revisions and consensus validation.
Leadership changes disclosed alongside the acquisition close add transition risk during an integration period. [#IR-2026-05-12]
The acquisition added financing risk because the $650M upfront payment used roughly $350M of cash on hand plus a $300M delayed-draw term loan. [#IR-2026-05-12]
The pain portfolio remains important to cash generation, so generic pressure, payer friction, or volume erosion could offset ADHD gains.

Peers

Symbol	Summary
AZTA	Similar market-cap bucket, but it is not a close operating peer; useful mainly as a small-cap biotech valuation check rather than a commercial pain/ADHD analog.
ORIC	Another small-cap biopharma comp with materially different pipeline economics; more helpful for risk appetite context than for matching Collegium’s cash-generating commercial mix.
MGTX	Loose same-size biotech comparison, but its gene-therapy profile is far less comparable than Collegium’s marketed-product model, underscoring that the peer set here is weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-03